The following was posted by me on 2nd Feb (801) in order to give investors a resume to the background of this drug-:
The lead project rejected by the FDA was a funding issue by the patent holder Arpida Biotech to conduct extensive phase 3 trials stipulated by the FDA.
This antibacterial compound has been in existence since Arpida Biotech first patented the compound approximately fifteen years ago. Iclaprim was hailed by analysts in some quarters after completing phase 2 trials. However, 2008 saw the credit crunch and no possibility of further funding Iclaprim into phase 3 trials. A merger with Evolva was intended to take the drug forward but Evolva changed business strategy towards natural herbal compounds.
Evolva sold Iclaprim to a licensing Biotech company called Acino who in turn were bought out by Pharma Strategy Partners. Five years on, Iclaprim is now owned by an un-named US licensing Biotech company.
Motif has done a deal to hopefully raise the necessary phase 3 funds through an IPO to continue Arpida Biotechs research into Iclaprim and take it to full FDA approval.
GC is the general chat section and riddler has his own thread, riddlers tehnicals its used by many to share tips nd views - click share chat, select general chat, select riddlers thread and go to last page and then read back the last few pages to get most recent views.
Amp holds over 11% of Kromek ( http://www.kromek.com/investor_shareholders.asp ) Current holding value £3.8m.(fully dilluted). Being involved in aviation security, well this surely is the height of the market for that right now. Also Datatern appeal ruling due end q1 could add millions to AMP's 100% holding of Datatern, same chairman too. And the 31st ipo of Motif of course, interesting few weeks ahead and more of Amp's long term investments finally coming though to real added true value for the market to see.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.